Kyoto University has disclosed compounds and their nanoparticles acting as radiosensitizers for radiotherapy reported to be useful for the treatment of cancer.
Cimeio Therapeutics Inc. has entered into a preclinical research collaboration with a researcher at the University of Pennsylvania (Penn) to research and evaluate a novel universal immunotherapy with potential to treat multiple blood and bone marrow cancers.
In recent years, the introduction of immune checkpoint inhibitors to the oncolytic pipeline has been a significant breakthrough in cancer treatment, but unfortunately some tumors respond only minimally. Besides CTLA-4, and since the approval of PD-1/PD-L1 inhibitors, only the anti-LAG3 strategy (relatlimab, Bristol Myers Squibb Co.) has been good enough to reach the market. In a session dealing with emerging checkpoints beyond PD-1, CTLA-4 and LAG3, Drew Rasco from the START Center for Cancer Care depicted a new player on the ground of immunotherapeutic options.
Sookmyung Women’s University has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, inflammation, autoimmune diseases and fibrosis.
Beigene Ltd. has divulged 4-(aminomethyl)-6-(1-methyl-1H-pyrazol-4-yl) isoquinolin-1 (2H)-one derivatives acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Insilico Medicine IP Ltd. has identified heteroaromatic compounds acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Duality Biologics (Suzhou) Co. Ltd. has synthesized antibody-drug conjugates comprising anti-GPC3 antibodies covalently linked to exatecan derivatives through a linker. They are reported to be useful for the treatment of cancer.
RSS
